676 related articles for article (PubMed ID: 34580494)
1. Pharmacological inhibition of fatty acid synthesis blocks SARS-CoV-2 replication.
Chu J; Xing C; Du Y; Duan T; Liu S; Zhang P; Cheng C; Henley J; Liu X; Qian C; Yin B; Wang HY; Wang RF
Nat Metab; 2021 Nov; 3(11):1466-1475. PubMed ID: 34580494
[TBL] [Abstract][Full Text] [Related]
2. The Fatty Acid Lipid Metabolism Nexus in COVID-19.
Tanner JE; Alfieri C
Viruses; 2021 Jan; 13(1):. PubMed ID: 33440724
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors of VPS34 and fatty-acid metabolism suppress SARS-CoV-2 replication.
Williams CG; Jureka AS; Silvas JA; Nicolini AM; Chvatal SA; Carlson-Stevermer J; Oki J; Holden K; Basler CF
Cell Rep; 2021 Aug; 36(5):109479. PubMed ID: 34320401
[TBL] [Abstract][Full Text] [Related]
4. Inhibitors of endosomal acidification suppress SARS-CoV-2 replication and relieve viral pneumonia in hACE2 transgenic mice.
Shang C; Zhuang X; Zhang H; Li Y; Zhu Y; Lu J; Ge C; Cong J; Li T; Tian M; Jin N; Li X
Virol J; 2021 Feb; 18(1):46. PubMed ID: 33639976
[TBL] [Abstract][Full Text] [Related]
5. Protective Effects of Astodrimer Sodium 1% Nasal Spray Formulation against SARS-CoV-2 Nasal Challenge in K18-hACE2 Mice.
Paull JRA; Luscombe CA; Castellarnau A; Heery GP; Bobardt MD; Gallay PA
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452519
[TBL] [Abstract][Full Text] [Related]
6. Effects of simeprevir on the replication of SARS-CoV-2 in vitro and in transgenic hACE2 mice.
Muturi E; Hong W; Li J; Yang W; He J; Wei H; Yang H
Int J Antimicrob Agents; 2022 Jan; 59(1):106499. PubMed ID: 34929295
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of host cell serine protease inhibitor MM3122 against SARS-CoV-2 for treatment and prevention of COVID-19.
Boon ACM; Bricker TL; Fritch EJ; Leist SR; Gully K; Baric RS; Graham RL; Troan BV; Mahoney M; Janetka JW
J Virol; 2024 May; 98(5):e0190323. PubMed ID: 38593045
[TBL] [Abstract][Full Text] [Related]
8. Glucosylceramide synthase inhibitors prevent replication of SARS-CoV-2 and influenza virus.
Vitner EB; Achdout H; Avraham R; Politi B; Cherry L; Tamir H; Yahalom-Ronen Y; Paran N; Melamed S; Erez N; Israely T
J Biol Chem; 2021; 296():100470. PubMed ID: 33639165
[TBL] [Abstract][Full Text] [Related]
9. Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19.
Mirabelli C; Wotring JW; Zhang CJ; McCarty SM; Fursmidt R; Pretto CD; Qiao Y; Zhang Y; Frum T; Kadambi NS; Amin AT; O'Meara TR; Spence JR; Huang J; Alysandratos KD; Kotton DN; Handelman SK; Wobus CE; Weatherwax KJ; Mashour GA; O'Meara MJ; Chinnaiyan AM; Sexton JZ
Proc Natl Acad Sci U S A; 2021 Sep; 118(36):. PubMed ID: 34413211
[TBL] [Abstract][Full Text] [Related]
10. Cellular host factors for SARS-CoV-2 infection.
Baggen J; Vanstreels E; Jansen S; Daelemans D
Nat Microbiol; 2021 Oct; 6(10):1219-1232. PubMed ID: 34471255
[TBL] [Abstract][Full Text] [Related]
11. The K18-Human ACE2 Transgenic Mouse Model Recapitulates Non-severe and Severe COVID-19 in Response to an Infectious Dose of the SARS-CoV-2 Virus.
Dong W; Mead H; Tian L; Park JG; Garcia JI; Jaramillo S; Barr T; Kollath DS; Coyne VK; Stone NE; Jones A; Zhang J; Li A; Wang LS; Milanes-Yearsley M; Torrelles JB; Martinez-Sobrido L; Keim PS; Barker BM; Caligiuri MA; Yu J
J Virol; 2022 Jan; 96(1):e0096421. PubMed ID: 34668775
[TBL] [Abstract][Full Text] [Related]
12. GNS561 Exhibits Potent Antiviral Activity against SARS-CoV-2 through Autophagy Inhibition.
Bestion E; Zandi K; Belouzard S; Andreani J; Lepidi H; Novello M; Rouquairol C; Baudoin JP; Rachid M; La Scola B; Mege JL; Dubuisson J; Schinazi RF; Mezouar S; Halfon P
Viruses; 2022 Jan; 14(1):. PubMed ID: 35062337
[TBL] [Abstract][Full Text] [Related]
13. Drugs, Metabolites, and Lung Accumulating Small Lysosomotropic Molecules: Multiple Targeting Impedes SARS-CoV-2 Infection and Progress to COVID-19.
Blaess M; Kaiser L; Sommerfeld O; Csuk R; Deigner HP
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670304
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 aberrantly elevates mitochondrial bioenergetics to induce robust virus propagation.
Shin HJ; Lee W; Ku KB; Yoon GY; Moon HW; Kim C; Kim MH; Yi YS; Jun S; Kim BT; Oh JW; Siddiqui A; Kim SJ
Signal Transduct Target Ther; 2024 May; 9(1):125. PubMed ID: 38734691
[TBL] [Abstract][Full Text] [Related]
15. Understanding Severe Acute Respiratory Syndrome Coronavirus 2 Replication to Design Efficient Drug Combination Therapies.
Ortega JT; Zambrano JL; Jastrzebska B; Liprandi F; Rangel HR; Pujol FH
Intervirology; 2020; 63(1-6):2-9. PubMed ID: 33099545
[TBL] [Abstract][Full Text] [Related]
16. Drug repurposing screens identify chemical entities for the development of COVID-19 interventions.
Bakowski MA; Beutler N; Wolff KC; Kirkpatrick MG; Chen E; Nguyen TH; Riva L; Shaabani N; Parren M; Ricketts J; Gupta AK; Pan K; Kuo P; Fuller M; Garcia E; Teijaro JR; Yang L; Sahoo D; Chi V; Huang E; Vargas N; Roberts AJ; Das S; Ghosh P; Woods AK; Joseph SB; Hull MV; Schultz PG; Burton DR; Chatterjee AK; McNamara CW; Rogers TF
Nat Commun; 2021 Jun; 12(1):3309. PubMed ID: 34083527
[TBL] [Abstract][Full Text] [Related]
17. The global succinylation of SARS-CoV-2-infected host cells reveals drug targets.
Liu Q; Wang H; Zhang H; Sui L; Li L; Xu W; Du S; Hao P; Jiang Y; Chen J; Qu X; Tian M; Zhao Y; Guo X; Wang X; Song W; Song G; Wei Z; Hou Z; Wang G; Sun M; Li X; Lu H; Zhuang X; Jin N; Zhao Y; Li C; Liao M
Proc Natl Acad Sci U S A; 2022 Jul; 119(30):e2123065119. PubMed ID: 35858407
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 Causes Lung Infection without Severe Disease in Human ACE2 Knock-In Mice.
Winkler ES; Chen RE; Alam F; Yildiz S; Case JB; Uccellini MB; Holtzman MJ; Garcia-Sastre A; Schotsaert M; Diamond MS
J Virol; 2022 Jan; 96(1):e0151121. PubMed ID: 34668780
[TBL] [Abstract][Full Text] [Related]
19. Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy.
Alonzi T; Aiello A; Petrone L; Najafi Fard S; D'Eletto M; Falasca L; Nardacci R; Rossin F; Delogu G; Castilletti C; Capobianchi MR; Ippolito G; Piacentini M; Goletti D
Cells; 2021 Dec; 11(1):. PubMed ID: 35011614
[TBL] [Abstract][Full Text] [Related]
20. Genome-Scale Metabolic Model of Infection with SARS-CoV-2 Mutants Confirms Guanylate Kinase as Robust Potential Antiviral Target.
Renz A; Widerspick L; Dräger A
Genes (Basel); 2021 May; 12(6):. PubMed ID: 34073716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
